Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

2018-01-30

Leukemia p. 1- 4

Additional Metadata
Persistent URL	doi.org/10.1038/s41375-018-0024-1, hdl.handle.net/1765/104934
Journal	Leukemia
Organisation	Department of Hematology
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Bringhen, S., Mina, R., Cafro, A.M. (Anna Maria), Liberati, A. M., Spada, S. (Stefano), Belotti, A. (Angelo), Gaidano, G. (Gianluca), Patriarca, F., Troia, R. (Rossella), Fanin, R., de Paoli, L. (Lorenzo), Rossi, G. (Giuseppe), Lombardo, A. (Alessandra), Bertazzoni, P. (Paola), Palumbo, A., Sonneveld, P.& Boccadoro, M. (2018). Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia, 1–4.https://doi.org/10.1038/s41375-018-0024-1

Publication